肝硬化
脂肪性肝炎
脂肪肝
肝星状细胞
肝癌
血管内皮生长因子
化学
炎症
纤维化
癌症研究
肝病
肝细胞癌
医学
免疫学
内科学
疾病
生物化学
血管内皮生长因子受体
作者
Rakesh Sahu,Sourav Goswami,G. Narahari Sastry,Ravindra K. Rawal
标识
DOI:10.1002/cbdv.202201029
摘要
Abstract Non‐alcoholic fatty liver disease (NAFLD) may vary from moderately mild non‐alcohol fatty liver (NAFL) towards the malignant variant known as non‐alcoholic steatohepatitis (NASH), which is marked by fatty liver inflammation and may progress to liver cirrhosis (LC), liver cancer, fibrosis, or liver failure. Flavonoids can protect the liver from toxins through their anti‐inflammatory, antioxidant, anti‐cancer, and antifibrogenic pharmacological activities. Furthermore, flavonoids protect against LC by regulation of hepatic stellate cells (HSCs) trans‐ differentiation, inhibiting growth factors like TGF‐β and platelets‐derived growth factor (PDGF), vascular epithelial growth factor (VEGF), viral infections like hepatitis‐B, C and D viruses (HBV, HCV & HDV), autoimmune‐induced, alcohol‐induced, metabolic disorder‐induced, causing by apoptosis, and regulating MAPK pathways. These flavonoids may be explored in the future as a therapeutic solution for hepatic diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI